Beckley Psytech Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 69

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $390M

Beckley Psytech General Information

Description

Developer of a clinical-stage biotechnology platform designed to upgrade psychedelics into effective medicines for neuropsychiatric disorders. The company's platform focuses on rigorous scientific research and deep expertise in drug development, enabling healthcare providers to access treatments that address significant unmet needs in patient care for conditions such as depression and anxiety.

Contact Information

Website
www.beckleypsytech.com
Formerly Known As
Beckley Psychedelics, Rivertime Distribution
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Beckley Park
  • Oxford OX3 9SY
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
AtaiBeckley
Vertical(s)
Life Sciences
Corporate Office
  • Beckley Park
  • Oxford OX3 9SY
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beckley Psytech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 03-Jun-2025 $390M Completed Clinical Trials - Phase 2
7. Later Stage VC 09-Apr-2025 Cancelled Clinical Trials - Phase 2
6. Later Stage VC (Series C) 03-Jan-2024 Completed Clinical Trials - Phase 2
5. Secondary Transaction - Private 01-Oct-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 15-Aug-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC 18-Dec-2020 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 28-May-2020 $3.69M $3.69M Completed Clinical Trials - Phase 1
1. Spin-Off 02-Aug-2018 Completed Clinical Trials - Phase 1
To view Beckley Psytech’s complete valuation and funding history, request access »

Beckley Psytech Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
B Ordinary
B Ordinary
A Ordinary
A Ordinary 9,999,999 $0.000100 $0.3 $0.3 1x $0.3 10.06%
Ordinary 18,000,000 $0.000100 $0.03 $0.03 1x $0.03 18.11%
To view Beckley Psytech’s complete cap table history, request access »

Beckley Psytech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical-stage biotechnology platform designed to upgrade psychedelics into effective medicines for neuro
Drug Discovery
Oxford, United Kingdom
69 As of 2025

New York, NY
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beckley Psytech Competitors (7)

One of Beckley Psytech’s 7 competitors is AtaiBeckley, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AtaiBeckley Formerly VC-backed New York, NY
Definium Therapeutics Formerly VC-backed New York, NY
Climb Bio Formerly VC-backed Wellesley Hills, MA
Cybin Formerly VC-backed Toronto, Canada
Braxia Scientific Formerly VC-backed Toronto, Canada
You’re viewing 5 of 7 competitors. Get the full list »

Beckley Psytech Patents

  • 159

    Total Documents Applications and Grants

  • Total Patents Families

  • 36

    Granted

  • 45

    Pending

  • Expiring in next 12 mo

Beckley Psytech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026234206-A1 Analogues of n-acetylserotonin and combinations of tropomyosin receptor kinase b (trkb) agonist and a mammalian target of rapamycin (mtor) inhibitor Pending 08-May-2025
GB-202507034-D0 Pharmaceutical compositions Pending 08-May-2025
GB-202507038-D0 Pharmaceutical compositions Pending 08-May-2025
GB-202505025-D0 Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) Pending 03-Apr-2025
WO-2026209976-A1 Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) Pending 03-Apr-2025 A61K9/19
To view Beckley Psytech’s complete patent history, request access »

Beckley Psytech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beckley Psytech Former Investors (38)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Aligned Ventures Venture Capital Minority
Ayuh Ventures Venture Capital Minority
Bail Capital Venture Capital Minority
Be the Earth Foundation Impact Investing Minority
You’re viewing 5 of 38 investors. Get the full list »

Beckley Psytech Acquisitions (2)

Beckley Psytech’s most recent deal was a Merger/Acquisition with Eleusis for . The deal was made on 20-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Eleusis 20-Oct-2022 Merger/Acquisition Drug Discovery
Amandala Neuro Merger/Acquisition Drug Discovery
To view Beckley Psytech’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Beckley Psytech Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Amandala Neuro London, United Kingdom 2017

Beckley Psytech FAQs

  • When was Beckley Psytech founded?

    Beckley Psytech was founded in 2018.

  • Where is Beckley Psytech headquartered?

    Beckley Psytech is headquartered in Oxford, United Kingdom.

  • What is the size of Beckley Psytech?

    Beckley Psytech has 69 total employees.

  • What industry is Beckley Psytech in?

    Beckley Psytech’s primary industry is Drug Discovery.

  • Is Beckley Psytech a private or public company?

    Beckley Psytech is a Private company.

  • What is the current valuation of Beckley Psytech?

    The current valuation of Beckley Psytech is .

  • What is Beckley Psytech’s current revenue?

    The current revenue for Beckley Psytech is .

  • How much funding has Beckley Psytech raised over time?

    Beckley Psytech has raised $143M.

  • Who are Beckley Psytech’s investors?

    Adage Capital Management, Aligned Ventures, Ayuh Ventures, Bail Capital, and Be the Earth Foundation are 5 of 38 investors who have invested in Beckley Psytech.

  • Who are Beckley Psytech’s competitors?

    AtaiBeckley, Definium Therapeutics, Climb Bio, Cybin, and Braxia Scientific are some of the 7 competitors of Beckley Psytech.

  • When was Beckley Psytech acquired?

    Beckley Psytech was acquired on 03-Jun-2025.

  • Who acquired Beckley Psytech?

    Beckley Psytech was acquired by AtaiBeckley.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process